Sneddon syndrome …

David S Liebeskind MD

Stroke & Vascular Disorders

Updated 04.21.2022
Released 04.10.1995
Expires For CME 04.21.2025

Sneddon syndrome

Author: David S Liebeskind MD

See Contributor Disclosures

Editor: Steven R Levine MD

Sneddon syndrome

In This Article

Quick Link

Introduction

Overview

Sneddon syndrome is characterized by livedo reticularis and cerebrovascular events. Clinical manifestations may include hypertension and associated coagulopathies. The underlying pathophysiology of this syndrome remains obscure, yet increasing recognition of this entity may further ongoing investigations. In this article, the author summarizes the clinical features and most recent data related to this syndrome.

Key points

	• Sneddon syndrome is typically characterized by livedo reticularis, a patchy, netlike, violaceous skin discoloration that typically appears on the trunk and extremities and spares the face.
	• Antiphospholipid antibodies have been associated with a significant number of cases of Sneddon syndrome, although absence or fluctuating titers may also occur.
	• The majority of reported cases of Sneddon syndrome are female and hypertensive, often without evidence of significant renal involvement.

Historical note and terminology

In 1965 British dermatologist I B Sneddon described 6 patients with "cerebrovascular incidents which have been of limited and benign nature" associated with "benign type" hypertension and livedo reticularis (87). The patients ranged in age from 20 to 42 years, with livedo reticularis often preceding the cerebral manifestations by many years. He was unable to identify an underlying disease in these patients, though specifically excluding syphilis, tuberculosis, systemic lupus erythematosus, and polyarteritis nodosa. Although the syndrome of stroke and livedo reticularis is linked in name to Sneddon, a similar idiopathic case of livedo reticularis and cerebral thromboses in a 39-year-old man with biopsy-proven endarteritis obliterans had been published 5 years prior to Sneddon's report (16). The initial association of ischemic stroke and livedo reticularis preceded both these accounts by more than 50 years in a case report describing a patient with syphilis (26).

Different perspectives have arisen in the literature regarding the nomenclature for the dermatologic phenomenon that Sneddon referred to as "livedo reticularis." European authors often use the term "livedo racemosa" to describe this irregular, dark netlike pattern that persists on warming and reserve the term "livedo reticularis" for the diffuse "cutis marmorata" phenomenon, a transient physiologic response to cold usually occurring in children (13; 91).

Clinical manifestations

Presentation and course

The characteristic dermatologic lesion of livedo reticularis is a fixed, patchy, netlike, violaceous skin discoloration, appearing typically on the trunk and extremities and sparing the face.

Livedo reticularis associated with Sneddon syndrome

Picture demonstrates skin discoloration of livedo reticularis in Sneddon syndrome. (Contributed by Dr. David Liebeskind.)

Livedo may develop concurrent with or precede the cerebrovascular symptoms by as many as 30 years, with an approximate average of 5 years. The dermatopathy occasionally develops after the neurologic manifestations.

Ischemic stroke, particularly in the territory of the middle cerebral artery, is the neurologic hallmark of Sneddon syndrome and has been documented to occur first between the ages of 10 and 64 years, with an average age of 42 years (88). Only a few pediatric cases have been described (102; 38; 41). Stroke may be preceded by episodes of dizziness and headache or transient ischemic attacks (103). Migraines may precede stroke, and migraineurs with livedo reticularis may be at increased risk of stroke (95). Headache frequency is not significantly higher in those with positive antiphospholipid antibodies, however (94). In rare exceptions, headache may be the only manifestation (14). Seizures occasionally occur, although usually late in the course of disease (87; 74; 81; 77; 32) and probably result from an ischemic or infarcted focus. One case described tremor as the initial neurologic manifestation of Sneddon syndrome (17). Cognitive impairment is likely related to recurrent stroke leading to vascular dementia (77; 76; 91), although some authors have reported that cognitive decline may occur in the absence of antecedent stroke (18; 79; 100; 01). A case report highlights that Sneddon syndrome may also become clinically manifest as cognitive impairment without typical stroke signs (61; 27). Both monocular and binocular ischemic events, presumably related to ophthalmic or retinal artery occlusion, have been documented in Sneddon syndrome (45; 72; 78). Isolated third cranial nerve palsy has been reported (44). Central retinal vein occlusion has been described as an initial manifestation (02). Peripheral retinal capillary occlusions with neovascularization have also been reported (37).

Labile hypertension was noted in 5 of the 6 patients originally described by Sneddon and has been reported in the majority of subsequently recognized cases. The basis for the blood pressure elevation in this syndrome is not well understood, as most of the hypertensive subjects have had no evidence of renal disease. Cardiac manifestations of Sneddon syndrome include ischemic heart disease and valvular abnormalities, particularly mitral valve thickening (74; 48; 29). Degeneration of the cardiac valves may also occur (21). The presence of left-sided cardiac disease raises the possibility that some of the ischemic strokes in Sneddon syndrome are cardioembolic in origin (22).

Other systemic vascular manifestations include mesenteric ischemia (51) and renal involvement (90; 71; 59).

Prognosis and complications

The natural history of Sneddon syndrome is not well characterized. Many persons, including those described by Sneddon, have suffered recurrent ischemic infarcts without significant clinical disability. A prospective longitudinal study of 13 cases of Sneddon syndrome described a relative benign course (10). Over a 6-year period, most individuals did not experience further neurologic events, although MRI findings suggested the development of additional subcortical lesions (10). In other instances, this progressive disorder is severely crippling and may lead to severe vascular dementia (89; 80; 13; 30). Although sensorimotor deficits may considerably improve, neuropsychological sequelae can be severely disabling, including suicidal behavior (98; 43). Limited data suggest that several factors influence prognosis. A single cerebrovascular event, the absence of angiographic evidence of intracranial occlusive disease (76), and the absence of antiphospholipid antibodies (48) may portend a better prognosis (88). Pregnancy or use of oral contraceptives may promote clinical deterioration in women (103). The mortality rate in 1 population was estimated at 9.5% within an average observation time of 6.2 years (103). Few studies have been published on long-term sequelae, yet some relate the chronic nature of the condition (33).

Clinical vignette

A 43-year-old woman presented with acute onset of right upper extremity weakness and numbness. She dropped a bottle from her hand and noted that she was unable to grasp objects. Her symptoms progressed to involve her face with consequent dysarthria, although she did not suffer any lower extremity involvement. On review of systems, she reported several prior episodes of visual blurring and other transient neurologic symptoms. Past medical history included hypertension. Livedo reticularis was apparent on her torso and upper extremities. Laboratory testing failed to identify the presence of antiphospholipid antibodies, but revealed homozygosity for Factor V Leiden mutation. Transesophageal echocardiography revealed thickening of the mitral valve with prolapse. MRI demonstrated an ischemic stroke in the left frontoparietal cortices within middle cerebral artery distribution. Empiric anticoagulation with adjusted-dose warfarin was initiated. At 6 months she had regained her prior deficits and continued symptom-free. Subsequent assays detected the presence of antiphospholipid antibodies.

Biological basis

Etiology and pathogenesis

The cause for the predilection for dermal and intracranial cerebral vessels is uncertain but may relate to a common antigenic stimulus or gene expression common to the 2 vascular beds whose tissues both arise from ectoderm. Although hypertension and cigarette smoking are commonly present, the young age of stroke onset and pathological data suggest that factors other than atherosclerosis are important in the pathogenesis of the syndrome. The predilection for women in their childbearing years suggests an etiologic role for estrogen (103). Antiphospholipid antibodies have been associated with a significant number of cases of Sneddon syndrome although absence (25) or fluctuating titers may also occur (88).

The pathogenesis of Sneddon syndrome is unknown. Although in many instances skin biopsies have been normal or nonspecific (87; 77; 80), it is generally agreed that this is an arteriopathy of small and medium sized vessels (75; 77; 91). The sensitivity of skin biopsy may be augmented by employing multiple deep punch biopsies in different areas of the livedo (99; 54). Endarteritis obliterans, referring to a noninflammatory obstruction of muscular arteries from an intimal endothelial proliferation within a fibromucinous matrix, has been described (16; 75) and may represent a primary vasculopathy. Thrombi in the artery lumen and perivascular lymphocytic infiltration have also been reported (49). Some authors have described a distinct histopathological time course with early inflammatory reactions ("endotheliitis") followed by subendothelial proliferation of smooth muscle cells and a late fibrotic stage associated with luminal stenosis (91; 84), suggesting that the syndrome results from systemic vasculitis. Although vasculopathic luminal compromise and consequent hypoperfusion is typically invoked as the cause of ischemia, distal thromboembolism may also occur (86). Evidence of a mild, chronic perivascular inflammatory reaction in the absence of vasculitis has been noted on skin biopsy (89). Digital artery biopsies in 7 subjects in whom skin biopsies had been normal (77) demonstrated intimal hyperplasia with luminal narrowing, focal zones of absent or reduplicated internal elastic lamina, and adventitial fibrosis. There was no evidence of inflammation, and immunofluorescent studies were all negative.

A paucity of detailed pathologic data from the brain and cerebral vessels in Sneddon syndrome has greatly hampered our understanding of the pathogenesis of stroke in this syndrome. Infrequent histopathologic observations have revealed a diffuse cerebral vasculopathy with musculoelastic hyperplasia (74; 11; 36; 32; 42). These findings are similar to the changes seen in dermal and digital arteries described above. Leptomeningeal biopsy in a single case revealed granulomatous infiltration, supporting the concept of an inflammatory etiology (11), although other specimens have been devoid of an inflammatory component (74; 36; 03). Temporal artery biopsies from patients with Sneddon syndrome have been normal (80; 72) or have shown various degrees of intimal hyperplasia and medial fibrosis (49).

Histological examination of a patient with Sneddon syndrome dying of noncardiac causes showed moderate coronary arteriosclerosis but no significant small artery pathology (80). An autopsied heart in a patient who had myocardial infarction showed multiple platelet thrombi of various ages in the small intramyocardial arterioles as well as a thickened aortic valve with an organizing platelet thrombus at the free margin of the noncoronary cusp (70). Another heart from a patient with Sneddon syndrome and myocardial infarction had multiple thrombi within myocardial arteries and intimal hyperplasia of the small and medium coronary arteries, in addition to mitral valve endocarditis (74). None of the patients had evidence of coronary vasculitis.

Observations from around the world that antiphospholipid antibodies, including anticardiolipin antibodies and lupus anticoagulant, are present in some subjects with Sneddon syndrome raises consideration that the antibodies play a role in the development of the syndrome (45; 55; 67; 97; 49; 62; 68; 60; 73). The mechanisms by which antiphospholipid antibodies theoretically contribute to ischemic brain and skin disease include inhibition of phospholipid-dependent endogenous anticoagulants (ie, antithrombin III, protein C, protein S, thrombomodulin), direct vascular endothelial damage (ie, antiendothelial cell antibodies), and antibody-mediated platelet activation, all of which may promote thrombosis. Autoimmune thrombocytopenia may also occur (66). The mechanism by which antiphospholipid antibodies might promote the characteristic vascular pathology is uncertain. Of the patients with Sneddon syndrome who have been screened for antiphospholipid antibodies, the percentage of positivity ranges from 0% to 86%, with a mean of 59% (40 of 68) (97; 50; 91). The reasons for the discrepancy are unclear but may include the known variability over time of antiphospholipid antibody titers in individuals, as well as a lack of a standard battery of tests for antiphospholipid antibodies, the lack of standardization of laboratory methods, and various definitions for positive and negative values. A large review of antiphospholipid antibody syndrome cited livedo reticularis in 20.4% and stroke in 13.1% of cases (15). A comparison of the clinical profiles of antiphospholipid antibody-positive subjects with Sneddon syndrome to their antibody-negative counterparts (Table 1) does not support considering these as 2 separate entities, acknowledging that only those with the antibodies meet clinical and immunological criteria for the primary antiphospholipid antibody syndrome. Concomitant coagulopathies may also be present in the absence of frank antiphospholipid antibody demonstration. An analysis of protein Z, a vitamin K-dependent glycoprotein coagulation inhibitor, in cases of Sneddon syndrome suggests that this factor may also play a role in the underlying pathophysiology (04). Antimitochondrial type M5 antibodies may also be observed, likely representing another manifestation of the associated autoimmune derangements (83). Sneddon syndrome has also been described in association with protein S deficiency (82).

Table 1. Sneddon Syndrome: Comparison of aPL+ and aPL- Patients

Feature	aPL+	aPL-
Gender (female) Age at onset (year) Age range (year) Number of years lived to reticularis-preceded stroke Hypertension Thrombocytopenia Miscarriages Cardiac valve abnormality Venous thrombosis	36/47 (a-e,g-i,k) 39.7 (a-e,g-i,k) 16-58 1-17 25/41 (a,b,d,i,g,k) 6/39 (a,b,g,k) 19/30 (a,b,d,g,k) 16/34 (a-d,g,k) 10/41 (a,b,d,g,k)	22/29 (b,f,j,k) 42 (b,f,j,k) 24-50 1-28 16/27 (b,j) 2/7 (b,j) 2/6 (b,k,f) 3/10 (b,k,f) 2/12(b,k,f)
(a) (45) (b) (49) (c) (55) (d) (60) (e) (62) (f) (63) (g) (67) (h) (68) (I) (73) (j) (91) (k) (97)

Analysis of the clinical manifestations in 46 consecutive cases confirmed similarities with or without the presence of antiphospholipid antibodies, although seizures, echocardiographic evidence of mitral regurgitation, and thrombocytopenia were more frequent in patients with antiphospholipid antibodies (35). An evolving list of serologic markers associated with Sneddon syndrome has been reported, including antiprothrombin antibodies (47) and antiendothelial cell antibodies (34). Anti-beta 2-glycoprotein 1 antibodies have also been detected in Sneddon syndrome, although the etiologic role of these factors has yet to be established (39).

Genetic factors appear to play a role in several of the reported cases of Sneddon syndrome, with first-degree relatives having either livedo reticularis (77; 97; 62; 57) or the full syndrome (77; 76; 73; 78; 93). The presence of antiphospholipid antibodies in family members of persons with Sneddon syndrome lends further credence to the theory that these antibodies play an important role in the development of the syndrome (97; 58; 73). Familial deficiency of antithrombin-III has been reported in association with Sneddon syndrome (23). A high prevalence of heterozygous factor V mutation has also been described in Sneddon syndrome (08), as has a single case of familial dysfibrinogenemia (52). Familial Sneddon syndrome has also been associated with a mutation in NOTCH3 (40).

Diagnostic workup

Table 3 offers a diagnostic approach to patients with livedo reticularis and cerebrovascular disease, with the emphasis on identification of specific disease processes that might present with a phenotype identical to Sneddon syndrome.

Table 3. Diagnostic Evaluation

Clinical examination specifically looking for:
	• peripheral embolic lesions (subungual hemorrhages) • retinal embolic material (ie, cholesterol) • joint involvement • skin lesions: malar rash, petechiae, chancres
Neuroimaging studies
	• head CT, preferably MRI/MRA • carotid Doppler to exclude extracranial disease • cerebral angiography as clinically indicated
Laboratory studies
	• antiphospholipid antibodies • m lupus anticoagulant (activated PTT, Russel viper venom test, KCT) • m anticardiolipin antibodies • m beta-2 glycoprotein-1 antibodies • VDRL, platelet count, hematocrit • Westergren erythrocyte sedimentation rate, antinuclear antigen, rheumatoid factor, serum protein electrophoresis, cryoglobulins, circulating immune complexes • purified protein electrophoresis • calcium • antithrombin III • Factor V Leiden mutation • fibrinogen assays
Skin biopsy
	• to exclude cholesterol emboli, vasculitis, atherosclerosis

Radiologic findings. In Sneddon syndrome, brain computed tomography and magnetic resonance imaging usually show single or multiple, small- to moderate-sized cerebral infarcts, with MRI being the more sensitive of the 2 imaging modalities (46). In a preliminary report of 39 subjects with Sneddon syndrome, all but 1 patient had ischemic lesions less than 3 cm in diameter (28), with the majority of lesions located in the superficial cortex. Another series described small, multifocal infarcts but with a predominance in the periventricular deep white matter (91). One comparison study of Sneddon syndrome with primary antiphospholipid antibody syndrome suggested a periventricular predominance of infarcts in Sneddon syndrome with leukoaraiosis and small lacunar lesions (30). The majority of patients with Sneddon syndrome have some degree of cortical atrophy (77; 80; 09; 48; 91). Intracerebral hemorrhage has been described in patients with Sneddon syndrome, more frequently occurring in the later stages of the disease (20; 19; 96; 24; 69; 03; 85; 101). One report describes hemorrhage as the presenting feature (53). Although the mechanism of hemorrhage is unfounded, hemorrhagic sequelae may result from the combination of hypertension and a chronic vasculopathy (24). Intraventricular hemorrhage may also occur (05). Cerebral microbleeds may be evident on susceptibility-weighted MRI sequences (56). Transcranial Doppler ultrasonography may reveal silent cerebral microembolism (86). Cerebral angiography, when abnormal, shows multiple occlusions of the distal branches of the cerebral arteries (87; 75; 77; 49). Moyamoya syndrome has also been described in the setting of Sneddon syndrome (31). Involvement of extracranial vessels is distinctly unusual. Cases of collateral circulation of the brain via anastomoses between intracranial vessels, across the dura and through the deep perforating vessels, have also been documented (77; 03). The angiographic findings should be distinguished from the angiomatoses of Divry-van Bogaert syndrome (07). Cerebral blood flow studies, such as HMPAO-SPECT (64; 65), may reveal perfusion deficits in the absence of structural brain lesions. Perfusion techniques may elucidate findings of cortical atrophy and the clinical observation of progressive cognitive decline in a subset of patients. Angiography of the digital arteries, similar to those in the brain, reveals multiple arterial occlusions, as well as segmental narrowing and dilatation (77).

References

01: Adair JC, Digre KB, Swanda RM, et al. Sneddon's syndrome: a cause of cognitive decline in young adults. Neuropsychiatry Neuropsychol Behav Neurol 2001;14:197-204. PMID 11513104
02: Aggermann T, Haas P, Binder S. Central retinal vein occlusion as a possible presenting manifestation of Sneddon syndrome. J Neuroophthalmol 2007;27(3):240-1. PMID 17895826
03: Aquino Gondim FA, Leacock RO, Subrammanian TA, Cruz-Flores S. Intracerebral hemorrhage associated with Sneddon's syndrome: is ischemia-related angiogenesis the cause. Case report and review of the literature. Neuroradiology 2003;45:368-72. PMID 12750866
04: Ayoub N, Esposito G, Barete S, Soria C, Piette JC, Frances C. Protein Z deficiency in antiphospholipid-negative Sneddon's syndrome. Stroke 2004;35:1329-32. PMID 15105516
05: Bayrakli F, Erkek E, Kurtuncu M, Ozgen S. Intraventricular hemorrhage as an unusual presenting form of Sneddon syndrome. World Neurosurg 2010;73(4):411-3. PMID 20849802
06: Belena JM, Nunez M, Cabeza R, Puig A. Sneddon's syndrome and anaesthesia. Anaesthesia 2004;59:622. PMID 15144315
07: Bersano A, Morbin M, Ciceri E, et al. The diagnostic challenge of Divry van Bogaert and Sneddon syndrome: report of three cases and literature review. J Neurol Sci 2016;364:77-83. PMID 27084221
08: Besnier R, Frances C, Ankri A, Aiach M, Piette JC. Factor V Leiden mutation in Sneddon syndrome. Lupus 2003;12:406-8. PMID 12765305
09: Blom RJ. Sneddon syndrome: CT, arteriography, and MR imaging. J Comput Assist Tomogr 1989;13(1):119-22. PMID 2910928
10: Boesch SM, Plorer AL, Auer AJ, et al. The natural course of Sneddon syndrome: clinical and magnetic resonance imaging findings in a prospective six year observation study. J Neurol Neurosurg Psychiatry 2003;74:542-4. PMID 12640088
11: Boortz-Marx RL, Clark HB, Taylor S, Wesa KM, Anderson DC. Sneddon's syndrome with granulomatous leptomeningeal infiltration. Stroke 1995;26:492-5. PMID 7886731
12: Bottin L, Frances C, de Zuttere D, Boelle PY, Muresan IP, Alamowitch S. Strokes in Sneddon syndrome without antiphospholipid antibodies. Ann Neurol 2015;77(5):817-29. PMID 25628239
13: Bruyn RP, van der Veen JP, Donker AJ, Valk J, Wolters EC. Sneddon's syndrome. Case report and literature review. J Neurol Sci 1987;79:243-53. PMID 3612175
14: Cavestro C, Richetta L, Pedemonte E, Asteggiano G. Sneddon's syndrome presenting with severe disabling bilateral headache. J Headache Pain 2009;10:211-3. PMID 19288055
15: Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019-27. PMID 11953980
16: Champion RH, Rook AJ. Livedo reticularis. Proc R Soc Med 1960;53:961-2. PMID 13692262
17: Da Silva AM, Rocha N, Pinto M, et al. Tremor as the first neurological manifestation of Sneddon's syndrome. Mov Disord 2005;20:248-51. PMID 15382213
18: Devuyst G, Sindic C, Laterre EC, Brucher JM. Neuropathological findings of a Sneddon's syndrome presenting with dementia not preceded by clinical cerebrovascular events. Stroke 1996;27:1008-10. PMID 8623093
19: Diez-Tejedor E, Lara M, Frank A, Gutierrez M, Barreiro P. Cerebral haemorrhage in Sneddon's syndrome. J Neurol 1990;237(Suppl):S78.
20: Dikova CH, Ouzounov N, Bosnev G. Combination of livedo reticularis and cerebrovascular lesions: Sneddon’s syndrome. Savr Med 1985;12:34-8.
21: Diosteanu R, Schuler G, Muller U. Cardiac valve degeneration in a patient with Sneddon syndrome. Clin Res Cardiol 2015;104(6):453-5. PMID 25479820
22: Dominguez F, Pieske B, Kelle S. Cardiac manifestations of Sneddon's syndrome. Int J Cardiol 2015;190:275-6. PMID 25932805
23: Donnet A, Khalil R, Terrier G, Koeppel MC, Njee BT, Aillaud MF. Cerebral infarction, livedo reticularis, and familial deficiency in Antithrombin-III (letter). Stroke 1992;23:611-2. PMID 1561697
24: Dupont S, Fenelon G, Saiag P, Sirmai J. Warfarin in Sneddon's syndrome. Neurology 1996;46:1781-2. PMID 8649599
25: Duval A, Darnige L, Glowacki F, et al. Livedo, dementia, thrombocytopenia, and endotheliitis without antiphospholipid antibodies: Seronegative antiphospholipid-like syndrome. J Am Acad Dermatol 2009;61(6):1076-8. PMID 19646781
26: Ehrmann S. Ein neues Gefassymptom bei Lues. Wien Med Wochenschr 1907;16:777-82.
27: Fabiani G, Martins RF, Koppe GL, Demartini Z Jr, Gatto LAM. Cognitive and psychiatric changes as first clinical presentation in sneddon syndrome. Dement Neuropsychol 2018;12(2):216-9. PMID 29988314
28: Farronay OW, Kalashnikova LA, Verschaguin NV, et al. Cerebrovascular and immunological studies in Sneddon's syndrome. Ann Neurol 1992;32:266.
29: Faustino A, Paiva L, Morgadinho A, et al. Cardiac involvement in antiphospholipid syndrome associated with Sneddon syndrome: a challenging diagnosis. Rev Port Cardiol 2014;33(2):115.e1-7. PMID 24513089
30: Fetoni V, Grisoli M, Salmaggi A, Carriero R, Girotti F. Clinical and neuroradiological aspects of Sneddon's syndrome and primary antiphospholipid antibody syndrome. A follow-up study. Neurol Sci 2000;21:157-64. PMID 11076004
31: Fierini F, Barilaro A, Giambene B, et al. Moyamoya in a patient with Sneddon's syndrome. Clin Neurol Neurosurg 2015;129:34-6. PMID 25528372
32: Floel A, Imai T, Lohmann H, Bethke F, Sunderkötter F, Droste DW. Therapy of Sneddon syndrome. Eur Neurol 2002;48:126-32. PMID 12373028
33: Forchhammer S, Metzler G, Ghoreschi K. Long-term follow-up of early-onset sneddon syndrome: a case report. JAAD Case Rep 2018;4(9):880-2. PMID 30306117
34: Frances C, Le Tonqueze M, Salohzin KV, et al. Prevalence of anti-endothelial cell antibodies in patients with Sneddon's syndrome. J Am Acad Dermatol 1995;33:64-8. PMID 7601948
35: Frances C, Papo T, Wechsler B, Laporte JL, Biousse V, Piette JC. Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. Medicine (Baltimore) 1999;78:209-19. PMID 16274063
36: Geschwind DH, FitzPatrick M, Mischel PS, Cummings JL. Sneddon's syndrome is a thrombotic vasculopathy: neuropathologic and neuroradiologic evidence. Neurology 1995;45:557-60. PMID 7898716
37: Gobert A. Sneddon's syndrome with bilateral peripheral retinal neovascularization. Bull Soc Belge Ophtalmol 1995;255:85-90. PMID 7496580
38: Gottlober P, Bezold G, Schaer A, et al. Sneddon's syndrome in a child. Br J Dermatol 2000;142:374-6. PMID 10730781
39: Granel F, de Maistre E, Challier B, Weber M, Schmutz JL. [Ischemic stroke in young patients and/or livedo: is it important to look for anti-beta 2-glycoprotein I antibodies.] Rev Med Interne 1998;19:709-12. PMID 9827442
40: Greisenegger EK, Llufriu S, Chamorro A, et al. A NOTCH3 homozygous nonsense mutation in familial Sneddon syndrome with pediatric stroke. J Neurol 2021;268(3):810-6. PMID 32980981
41: Heesen M, Rossaint R. Anaesthesiological considerations in patients with Sneddon's syndrome. Paediatr Anaesth 2000;10:678-80. PMID 11119204
42: Hilton DA, Footitt D. Neuropathological findings in Sneddon's syndrome. Neurology 2003;60:1181-2. PMID 12682330
43: Hsu FF, Chung KH. Psychosis with suicide attempt in Sneddon syndrome. Psychiatry Clin Neurosci 2017;71(2):147-8. PMID 27891710
44: Jimenez-Gallo D, Albarran-Planelles C, Linares-Barrios M, Gonzalez-Fernandez JA, Espinosa-Rosso R, Baez-Perea JM. Sneddon syndrome presenting with unilateral third cranial nerve palsy. J Neuroophthalmol 2014;34(1):50-2. PMID 24051423
45: Jonas J, Kolble K, Volcker HE, Kalden JR. Central retinal artery occlusion in Sneddon's disease associated with antiphospholipid antibodies. Am J Ophthalmol 1986;102:37-9. PMID 3524244
46: Junqueira PH, Puglia P Jr, Amaral LL, Hoshino M. Sneddon syndrome - imaging findings. Arq Neuropsiquiatr 2016;74(1):83-4. PMID 26486491
47: Kalashnikova LA, Korczyn AD, Shavit S, Rebrova O, Reshetnyak T, Chapman J. Antibodies to prothrombin in patients with Sneddon's syndrome. Neurology 1999;53:223-5. PMID 10408567
48: Kalashnikova LA, Nasonov EL, Borisenko VV, et al. Sneddon's syndrome: cardiac pathology and antiphospholipid antibodies. Clin Exp Rheumatol 1991;9:357-61. PMID 1934683
49: Kalashnikova LA, Nasonov EL, Kushekbaeva AE, Gracheva LA. Anticardiolipin antibodies in Sneddon's syndrome. Neurology 1990;40:464-7. PMID 2314589
50: Kalashnikova LA, Nasonov EL, Stoianovich LZ, Kovalev Viu, Kosheleva NM, Reshetniak TM. Sneddon's syndrome and the primary antiphospholipid syndrome. Terapevticheskii Arkhiv 1993;65(3):64-70. PMID 8059389
51: Khoo LA, Belli AM. Superior mesenteric artery stenting for mesenteric ischaemia in Sneddon's syndrome. Br J Radiol 1999;72:607-9. PMID 10560345
52: Khosrotehrani K, Leroy-Matheron C, Mourier C, Revuz J, Bagot M. Sneddon syndrome revealing dysfibrinogenemia. Int J Dermatol 2003;42:561-2. PMID 12839611
53: Kraemer M, Berlit P. Cerebral haemorrhage as the presenting form of Sneddon's syndrome. Clin Neurol Neurosurg 2008;110(5):533. PMID 18367321
54: Legierse CM, Canninga-Van Dijk MR, Bruijnzeel-Koomen CA, Kuck-Koot VC. Sneddon syndrome and the diagnostic value of skin biopsies - three young patients with intracerebral lesions and livedo racemosa. Eur J Dermatol 2008;18(3):322-8. PMID 18474464
55: Levine SR, Langner SL, Albers JW, Welch KM. Sneddon's syndrome: an antiphospholipid antibody syndrome. Neurology 1988;38:798-800. PMID 3129674
56: Llufriu S, Cervera A, Capurro S, Chamorro A. Neurological picture. Familial Sneddon's syndrome with microbleeds in MRI. J Neurol Neurosurg Psychiatry 2008;79(8):962. PMID 18645217
57: Lossos A, Ben-Hur T, Ben-Nariah Z, Enk C, Gomori M, Soffer D. Familial Sneddon's syndrome. J Neurol 1995;242:164-8. PMID 7751860
58: Lousa M, Sastre JL, Cancelas JA, Gobernado JM, Pardo A. Study of antiphospholipid antibodies in a patient with Sneddon's syndrome and her family. Stroke 1994;25:1071-4. PMID 8165682
59: Macario F, Macario MC, Ferro A, Goncalves F, Campos M, Marques A. Sneddon's syndrome: a vascular systemic disease with kidney involvement. Nephron 1997;75:94-7. PMID 9031277
60: Manganelli P, Lisi R, Saginario A, Beroldi D. Sneddon's syndrome and primary antiphospholipid syndrome. A case report. J Am Acad Dermatol 1992;26:309-11. PMID 1569247
61: Marianetti M, Mina C, Marchione P, Giacomini P. Sneddon's Syndrome presenting with topographic disorientation. J Clin Neurosci 2011;18(7):980-1. PMID 21565509
62: Martinelli A, Martinelli P, Ippolito M, Guiliani S, Coccagna G. Sneddon syndrome presenting with hemicrania attacks: a case report. Acta Neurol Scand 1991;83:201-3. PMID 1815538
63: Martinez-Menendez B, Perez-Sempere A, Gonzalez-Rubino M, Villaverde-Amundarain FJ, Bermego-Pareja F. Sneddon's syndrome with negative antiphospholipid antibodies. Stroke 1990;21:1510-1. PMID 2219221
64: Menzel C, Reinhold U, Grunwald F, et al. Cerebral blood flow in Sneddon syndrome. J Nucl Med 1994;35:461-4. PMID 8113897
65: Meusser S, Rubbert A, Manger B, et al. 99m-Tc-HMPAO-SPECT in diagnosis of early cerebral vasculitis. Rheumatol Int 1996;16:37-42. PMID 8783421
66: Meyer O, Worm M, Kiesewetter H, Salama A. Autoimmune thrombocytopenia in two patients with Sneddon's Syndrome. Thromb Haemost 2007;98(6):1368-70. PMID 18064338
67: Montalban J, Ordi J, Barquinero J, Vilardell M. Sneddon's syndrome and anticardiolipin antibodies (letter). Stroke 1988;19:785-6. PMID 3376175
68: Moral A, Vidal JM, Moreau I, D'Olnaberriague L, Montalban J. Sneddon's syndrome with antiphospholipid antibodies and arteriopathy. Stroke 1991;22:1327-8. PMID 1926249
69: Muerza FM, Gonzalez G, Ortiz E, Saracibar N. [Cerebral hemorrhage in Sneddon syndrome]. Rev Neurol 1998;27:74-6. PMID 9674030
70: Murphy JJ, Leach IH. Findings at necropsy in the heart of a patient with anticardiolipin syndrome. Br Heart J 1989;62:61-4. PMID 2757875
71: Ohtani H, Imai H, Yasuda T, et al. A combination of livedo racemosa, occlusion of cerebral blood vessels, and nephropathy: kidney involvement in Sneddon's syndrome. Am J Kidney Dis 1995;26:511-5. PMID 7645561
72: Pauranik A, Parwani S, Jain S. Simultaneous bilateral central retinal arterial occlusion in a patient with Sneddon syndrome: case history. Angiology 1987;38(2 Pt 1):158-63. PMID 3826753
73: Pettee AD, Wasserman BA, Adams NL, et al. Familial Sneddon's syndrome: clinical, hematologic and radiographic findings in two brothers. Neurology 1994;44:399-405. PMID 8145905
74: Pinol Aguade J, Ferrandiz C, Ferrer Roca O, Ingelmo M. [Livedo reticularis and cerebro-vascular accidents] [Article in Spanish] Med Cutan Ibero Lat Am 1975;3(4):257-65. PMID 1241080
75: Quimby SR, Perry HO. Livedo Reticularis and cerebrovascular accidents. J Am Acad Dermatol 1980;3:377-83. PMID 6107309
76: Rautenberg W, Hennerici M, Aulich A, Holzke E, Lakomek HJ. Immunosuppressive therapy and Sneddon's syndrome. Lancet 1988;2:629-30. PMID 2901006
77: Rebollo M, Val JF, Garijo F, Quintana GF, Berciano J. Livedo Reticularis and cerebrovascular lesions (Sneddon's syndrome). Brain 1983;106:965-79. PMID 6652469
78: Rehany U, Kassif Y, Rumelt S. Sneddon's syndrome: neuro-ophthalmologic manifestations in a possible autosomal recessive pattern. Neurology 1998;51:1185-7. PMID 9781555
79: Rich MW. Sneddon syndrome and dementia. Mayo Clin Proc 1999;74:1306. PMID 10593361
80: Rumpl E, Neuthofer J, Pallua A, et al. Cerebrovascular lesions and livedo reticularis (Sneddon's syndrome)—a progressive cerebrovascular disorder. J Neurol 1985;231:324-30. PMID 3973641
81: Rumpl E, Rumpl H. Recurrent transient global amnesia in a case with cerebro-vascular lesions and livedo reticularis (Sneddon syndrome). J Neurol 1979;221:127-31. PMID 92541
82: Sayin R, Bilgili SG, Karadag AS, Tombul T. Sneddon syndrome associated with Protein S deficiency. Indian J Dermatol Venereol Leprol 2012;78(3):407. PMID 22565458
83: Seinturier C, Imbert B, Ponard D, Drouet C, Debru JL. [Sneddon syndrome with anti-mitochondrial type M5 antibodies]. Presse Med 2005;34:1011-2. PMID 16225256
84: Sepp N, Zelger B, Schuler G, Romani N, Fritsch P. Sneddon's syndrome--an inflammatory disorder of small arteries followed by smooth muscle proliferation. Immunohistochemical and ultrastructural evidence. Am J Surg Pathol 1995;19:448-53. PMID 7694946
85: Serrano-Pozo A, Gomez-Aranda F, Franco-Macias E, Serrano-Cabrera A. [Cerebral haemorrhage in Sneddon's syndrome: case report and literature review]. Rev Neurol 2004;39:731-3. PMID 15514901
86: Sitzer M, Sohngen D, Siebler M, et al. Cerebral microembolism in patients with Sneddon's syndrome. Arch Neurol 1995;52:271-5. PMID 7872880
87: Sneddon IB. Cardiovascular lesions and livedo reticularis. Br J Dermatol 1965;77:180-5. PMID 14278790
88: Starmans NLP, van Dijk MR, Kappelle LJ, Frijns CJM. Sneddon syndrome: a comprehensive clinical review of 53 patients. J Neurol 2021;268(7):2450-7. PMID 33515066
89: Stephens WP, Ferguson IT. Livedo reticularis and cerebrovascular disease. Postgrad Med J 1982;58:70-3. PMID 7100027
90: Stevens JM, Hunt JE, Seymour AE, Krilis SA, Pugsley DJ. Sneddon's syndrome, anti-cardiolipin antibody and glomerular thrombosis. Clin Nephrol 1994;41:18-22. PMID 8137565
91: Stockhammer G, Felber SR, Zelger B, et al. Sneddon's syndrome: diagnosis by skin biopsy and MRI in 17 patients. Stroke 1993;24:685-90. PMID 8488523
92: Sun J, Zhang F, Gao F, Wang J, Selim M, Lou M. Intravenous thrombolysis in Sneddon's syndrome. J Clin Neurosci 2012;19(2):326-8. PMID 22118882
93: Szmyrka-Kaczmarek M, Daikeler T, Benz D, Koetter I. Familial inflammatory Sneddon's syndrome-case report and review of the literature. Clin Rheumatol 2005;24:79-82. PMID 15340865
94: Tietjen GE, Al-Qasmi MM, Gunda P, Herial NA. Sneddon's syndrome: another migraine-stroke association. Cephalalgia 2006;26(3):225-32. PMID 16472327
95: Tietjen GE, Al-Qasmi MM, Shukairy MS. Livedo reticularis and migraine: a marker for stroke risk. Headache 2002;42:352-5. PMID 12047335
96: Uitdehaag BM, Scheltens P, Bertelsmann FW, Bruyn RP. Intracerebral haemorrhage in Sneddon's syndrome. J Neurol Sci 1992;111:227-8. PMID 1431991
97: Vargas JA, Yerba M, Pasqual ML, Manzano L, Durantez A. Antiphospholipid antibodies and Sneddons syndrome (letter). Am J Med 1989;87:597. PMID 2816979
98: Weissenborn K, Ruckert N, Ehrenheim C, Schellong S, Goetz C, Lubach D. Neuropsychological deficits in patients with Sneddon's syndrome. J Neurol 1996;243:357-63. PMID 8965111
99: Wohlrab J, Fischer M, Wolter M, Marsch WC. Diagnostic impact and sensitivity of skin biopsies in Sneddon's syndrome. A report of 15 cases. Br J Dermatol 2001;145:285-8. PMID 11531793
100: Wright RA, Kokmen E. Gradually progressive dementia without discrete cerebrovascular events in a patient with Sneddon's syndrome. Mayo Clin Proc 1999;74:57-61. PMID 9987534
101: Yao M, Zhao J, Jiang N, Li L, Ni J. Superficial siderosis and microbleed restricted in cortex might be correlated to atrophy and cognitive decline in Sneddon's syndrome. Front Neurol 2020;11:1035. PMID 33041979
102: Zaccariotti VA, Martins LF, da Costa V, Silva NA, da Casas AA, de Melo-Souza SE. Sneddon syndrome. Report of 3 cases. Arq Neuropsiquiatr 1995;53:82-7. PMID 7575213
103: Zelger B, Sepp N, Stockhammer G, et al. Sneddon's syndrome. A long-term follow-up of 21 patients. Arch Dermatol 1993;129:437-47. PMID 8466214

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

David S Liebeskind MD

Dr. Liebeskind of the University of California, Los Angeles, received consulting fees for core lab activities from Cerenovus, Genentech, Medtronic, Rapid Medical, and Stryker.
See Profile

Editor

Steven R Levine MD

Dr. Levine of the SUNY Health Science Center at Brooklyn has no relevant financial relationships to disclose.
See Profile

Former Authors

Steven R Levine MD and Gretchen E Tietjen MD (original authors)

Patient Profile

Age range of presentation: 6 to 65+ years
Sex preponderance: female>male, >2:1
Heredity: heredity may be a factor
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Polyarteritis nodosa and allied conditions: 446
ICD-10: Other conditions related to polyarteritis nodosa: M30.820
OMIM: Sneddon syndrome: #182410

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Sneddon syndrome

Associated Disorders

Hypertension
Ischemic heart disease
Systemic lupus erythematosus

Differential Diagnosis

disorders associated with livedo reticularis
systemic lupus erythematosus
polyarteritis nodosa
rheumatoid arthritis
tuberculosis
- syphilis
- hypercalcemia
- antiphospholipid antibody
- thrombotic thrombocytopenia purpura
- thrombocythemia
- disseminated intravascular coagulation
- neoplasm
- cryoglobulinemia
- atherosclerosis
- cholesterol emboli syndrome
- livedo reticularis associated with oral contraceptive use

Also Relevant

Antiphospholipid antibody syndrome
Cerebral vasculitis presenting with dementia
Hypercoagulable states and cerebrovascular disease
Ischemic stroke
Stroke in young adults

Clinical Categories

Stroke & Vascular Disorders

	• Collagen vascular disease, including systemic lupus erythematosus, polyarteritis nodosa, rheumatoid arthritis
	• Infectious diseases, including tuberculosis, syphilis
	• Metabolic derangement, including hypercalcemia
	• Hematologic abnormalities, including antiphospholipid antibody, thrombotic thrombocytopenia purpura, thrombocythemia, disseminated intravascular coagulation
	• Drugs, including oral contraceptives
	• Neoplasm
	• Cryoglobulinemia
	• Atherosclerosis, cholesterol emboli syndrome

Sneddon syndrome

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Table 1. Sneddon Syndrome: Comparison of aPL+ and aPL- Patients

Epidemiology

Prevention

Differential diagnosis

Table 2. Differential Diagnosis of Livedo Reticularis

Diagnostic workup

Table 3. Diagnostic Evaluation

Management

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Vein of Galen malformations

Patent foramen ovale

Neuroimaging in acute stroke

Atrial myxoma

Anterior cerebral artery stroke syndromes

Hemorrhagic transformation of ischemic stroke

Intracerebral hemorrhage due to thrombolytic therapy

White matter abnormalities in the brain

This is an article preview.
Start a Free Account
to access the full version.